{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"PFE","limit":50},"count":50,"signals":[{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"f our current Directors (other than Dr. Albert Bourla) are independent of the company and its management and meet Pfizers criteria for independence. The independent Directors are Drs. Susan Desmond-Hellmann, Scott Gottlieb, Susan Hockfield and Dan R. Littman; Ms. Suzanne Nora Johnson; and Messrs. Ronald E. Blaylock, Mortimer J. Buckley, Joseph J. Echevarria, Shantanu Narayen, James Quincey, James C.","filed_date":"2026-03-12","accession":"0000078003-26-000033","full_text":"https://origin.rootz.global/static/filing/0000078003-26-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"factors, as well as the maximum potentialpayouts. Based on the results of these assessments, the Committee does not believe the compensation programs create risks that are reasonably likely to have a material adverse effect on the company. Leading Compensation Practices | | | What We Do | What We Do Not Do | | | | 100% Performance-Based Annual Long-Term Incentives | | Permit Hedging or Pledging of Pfizer Stock | | | | M","filed_date":"2026-03-12","accession":"0000078003-26-000033","full_text":"https://origin.rootz.global/static/filing/0000078003-26-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":40,"context":"g optimization program, which is on track to deliver approximately $1.5 billion in net cost savings by the end of 2027.In 2025, we returned $9.8 billion to shareholders via our quarterly dividend and invested $10.4 billion in internal R&D and approximately $8.8 billion in business development transactions, primarily reflecting the Metsera acquisition and the 3SBio licensing deal. Our capital allocation strategy is desi","filed_date":"2026-03-12","accession":"0000078003-26-000033","full_text":"https://origin.rootz.global/static/filing/0000078003-26-000033.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":41,"context":"example, approximately $500 million of R&D savings achieved from our ongoing realigning our cost base program in 2025 is expected to be reinvested in R&D programs in 2026. See the [Costs and ExpensesRestructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives](#i8b50a6660a8d4e9ca2cc36f05ea41a36_127) section within MD&A for more information. We manage R&D operations on","filed_date":"2026-02-26","accession":"0000078003-26-000026","full_text":"https://origin.rootz.global/static/filing/0000078003-26-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":13,"context":"Australia, certain Eastern European countries, South Korea, Finland and New Zealand | | | DMD | Duchenne muscular dystrophy | | | EC | European Commission | | | EMA | European Medicines Agency | | | Emerging Markets | Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe (excluding the Balkans and certain other countries), Africa, the Middl","filed_date":"2026-02-26","accession":"0000078003-26-000026","full_text":"https://origin.rootz.global/static/filing/0000078003-26-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"d monetary policy actions in countries experiencing high inflation or deflation rates; any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues; the impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain; any significant issues related to the outsourcing of certain operationa","filed_date":"2026-02-26","accession":"0000078003-26-000026","full_text":"https://origin.rootz.global/static/filing/0000078003-26-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":25,"context":"| | Collaboration and Co-Promotion Agreements | 6 | | | International Operations | 7 | | | Sales and Marketing | 7 | | | Patents and Other Intellectual Property Rights | 7 | | | Competition | 9 | | | Pricing Pressures and Managed Care Organizations | 10 | | | Raw Materials | 11 | | | Government Regulation and Price Constraints | 11 | | | Environmental Matters | 14 | | | Our People | 15 | | | ITEM1A. RISK FACTORS","filed_date":"2026-02-26","accession":"0000078003-26-000026","full_text":"https://origin.rootz.global/static/filing/0000078003-26-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":74,"context":"995. The occurrence of any of the risks identified below, in the [Item 1A. Risk Factors](#i8b50a6660a8d4e9ca2cc36f05ea41a36_70) section, or within MD&A, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results of operations, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequent","filed_date":"2026-02-26","accession":"0000078003-26-000026","full_text":"https://origin.rootz.global/static/filing/0000078003-26-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":23,"context":"(a) | 2,546 | 2,598 | 7,231 | 7,787 | | | Acquired in-process research and development expenses | 1,390 | 13 | 1,401 | 20 | | | Amortization of intangible assets | 1,223 | 1,312 | 3,644 | 3,927 | | | Restructuring charges and certain acquisition-related costs | 286 | 313 | 945 | 1,669 | | | | | Other (income)/deductionsnet | 517 | 243 | 2,210 | 2,030 | | | Income from continuing operations before provision/(benefit) f","filed_date":"2025-11-04","accession":"0000078003-25-000150","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000150.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"nd defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our res","filed_date":"2025-11-04","accession":"0000078003-25-000150","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000150.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":24,"context":"expenses(a) | 2,482 | 2,696 | 4,685 | 5,189 | | | Acquired in-process research and development expenses | 2 | 6 | 11 | 6 | | | Amortization of intangible assets | 1,211 | 1,307 | 2,421 | 2,615 | | | Restructuring charges and certain acquisition-related costs | (18) | 1,254 | 660 | 1,356 | | | | | Other (income)/deductionsnet | 739 | 1,107 | 1,692 | 1,787 | | | Income/(loss) from continuing operations before provision","filed_date":"2025-08-05","accession":"0000078003-25-000138","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"nd defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our res","filed_date":"2025-08-05","accession":"0000078003-25-000138","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ears interest only after Maturity, interest payable after Maturity.  **Interest Payment Date:** The term Interest Payment Date shall mean, with respect to any Security, the Stated Maturity of an installment of interest on such Security.  **Issuer:** The term Issuer shall mean the Person named as the Issuer in the first paragraph of this Indenture until a successor Person shall have become such pursua","filed_date":"2025-05-19","accession":"0001193125-25-122480","full_text":"https://origin.rootz.global/static/filing/0001193125-25-122480.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":19,"context":",031 | 3,495 | | | Research and development expenses(a) | 2,203 | 2,493 | | | Acquired in-process research and development expenses | 9 | | | | Amortization of intangible assets | 1,211 | 1,308 | | | Restructuring charges and certain acquisition-related costs | 678 | 102 | | | | | Other (income)/deductionsnet | 953 | 680 | | | Income from continuing operations before provision/(benefit) for taxes on income | 2,785 | 3","filed_date":"2025-05-05","accession":"0000078003-25-000114","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000114.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"nd defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our res","filed_date":"2025-05-05","accession":"0000078003-25-000114","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000114.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"f our current Directors (other than Dr. Albert Bourla) are independent of the company and its management and meet Pfizers criteria for independence. The independent Directors are Drs. Susan Desmond-Hellmann, Scott Gottlieb, Helen H. Hobbs, Susan Hockfield and Dan R. Littman; Ms. Suzanne Nora Johnson; and Messrs. Ronald E. Blaylock, Mortimer J. Buckley, Joseph J. Echevarria, Shantanu Narayen, James Qu","filed_date":"2025-03-13","accession":"0000078003-25-000062","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"rs, as well as the maximum potentialpayouts. Based on the results of these assessments, the Committee does not believe that the compensation programs create risks that are reasonably likely to have a material adverse effect on our company. Leading Compensation Practices | | | What We Do | What We Do Not Do | | | | 100% Performance-Based Annual Long-Term Incentives | | Permit Hedging or Pledging of Pfizer Stock | | | | M","filed_date":"2025-03-13","accession":"0000078003-25-000062","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"ur business at an appropriate level of financial return and making share repurchases after de-levering our balance sheet. In 2024, we returned $9.5 billion to shareholders via our quarterly dividend, invested $10.8 billion in internal R&D and paid down approximately $7.8 billion in debt.HELPING PATIENTSWith 14 approvals received in 2024 from the U.S. Food and Drug Administration or the European Medicines Agency, we adv","filed_date":"2025-03-13","accession":"0000078003-25-000062","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":46,"context":"cture changes, and product portfolio enhancements. See [Note 3](#i8531e747ebb543f3bf818166f157d26a_199). For a description of anticipated savings related to these programs, see the [Costs and ExpensesRestructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives](#i8531e747ebb543f3bf818166f157d26a_124) section within MD&A. R&D: We believe we have a strong pipeline and ar","filed_date":"2025-02-27","accession":"0000078003-25-000054","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":17,"context":"Australia, Scandinavian countries, South Korea, the Balkans, New Zealand and Finland | | | DMD | Duchenne muscular dystrophy | | | EC | European Commission | | | EMA | European Medicines Agency | | | Emerging Markets | Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, the Middle East, Eastern Europe (excluding the Balkans) and Turkey | | | EPS","filed_date":"2025-02-27","accession":"0000078003-25-000054","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"d monetary policy actions in countries experiencing high inflation or deflation rates; any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues; the impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain; any significant issues related to the outsourcing of certain operationa","filed_date":"2025-02-27","accession":"0000078003-25-000054","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":24,"context":"| | Collaboration and Co-Promotion Agreements | 5 | | | International Operations | 6 | | | Sales and Marketing | 6 | | | Patents and Other Intellectual Property Rights | 7 | | | Competition | 9 | | | Pricing Pressures and Managed Care Organizations | 9 | | | Raw Materials | 10 | | | Government Regulation and Price Constraints | 10 | | | Environmental Matters | 13 | | | Our People | 14 | | | ITEM1A. RISK FACTORS |","filed_date":"2025-02-27","accession":"0000078003-25-000054","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":68,"context":"995. The occurrence of any of the risks identified below, in the [Item 1A. Risk Factors](#i8531e747ebb543f3bf818166f157d26a_67) section, or within MD&A, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results of operations, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequent","filed_date":"2025-02-27","accession":"0000078003-25-000054","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":12,"context":"cess research and development expenses | | 88 | | | 73 | | | 21 | | 108 | | | 194 | | | (44) | | | Amortization of intangible assets | | 1,359 | | | 1,267 | | | 7 | | 5,286 | | | 4,733 | | | 12 | | | Restructuring charges and certain acquisition-related costs(4) | | 750 | | | 2,566 | | | (71) | | 2,419 | | | 2,943 | | | (18) | | | | | | | | | | | | | | | | | | Other (income)deductionsnet(5) | | 2,358 | | | (159) | | |","filed_date":"2025-02-04","accession":"0000078003-25-000017","full_text":"https://origin.rootz.global/static/filing/0000078003-25-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":21,"context":"enses(b) | 2,598 | 2,711 | 7,787 | 7,864 | | | Acquired in-process research and development expenses | 13 | 67 | 20 | 122 | | | Amortization of intangible assets | 1,312 | 1,179 | 3,927 | 3,466 | | | Restructuring charges and certain acquisition-related costs | 313 | 155 | 1,669 | 377 | | | | | Other (income)/deductionsnet | 243 | 181 | 2,030 | 381 | | | Income/(loss) from continuing operations before provision/(benef","filed_date":"2024-11-04","accession":"0000078003-24-000191","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000191.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":6,"context":"nd defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our res","filed_date":"2024-11-04","accession":"0000078003-24-000191","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000191.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":12,"context":"ss research and development expenses | | 13 | | | 67 | | | (80) | | 20 | | | 122 | | | (84) | | | Amortization of intangible assets | | 1,312 | | | 1,179 | | | 11 | | 3,927 | | | 3,466 | | | 13 | | | Restructuring charges and certain acquisition-related costs(4) | | 313 | | | 155 | | | * | | 1,669 | | | 377 | | | * | | | | | | | | | | | | | | | | | | Other (income)deductionsnet(5) | | 243 | | | 181 | | | 34 | | 2,030","filed_date":"2024-10-29","accession":"0000078003-24-000188","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000188.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":22,"context":"expenses(b) | 2,696 | 2,648 | 5,189 | 5,153 | | | Acquired in-process research and development expenses | 6 | 33 | 6 | 55 | | | Amortization of intangible assets | 1,307 | 1,184 | 2,615 | 2,287 | | | Restructuring charges and certain acquisition-related costs | 1,254 | 214 | 1,356 | 222 | | | | | Other (income)/deductionsnet | 1,107 | (75) | 1,787 | 200 | | | Income/(loss) from continuing operations before provision/(","filed_date":"2024-08-05","accession":"0000078003-24-000166","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000166.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":6,"context":"nd defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our res","filed_date":"2024-08-05","accession":"0000078003-24-000166","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000166.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":13,"context":"S attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP. (5)Second-quarter 2024 Reported(4) diluted EPS was unfavorably impacted by $0.18 resulting from a $1.3 billion one-time restructuring charge related to the Manufacturing Optimization Program. (6)The targeted $4 billion in net cost savings is calculated versus the midpoint of Pfizers 2023 SIA and RD expense guidance provided on August 1, 2","filed_date":"2024-07-30","accession":"0000078003-24-000155","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000155.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":15,"context":"495 | 3,418 | | | Research and development expenses(b) | 2,493 | 2,505 | | | Acquired in-process research and development expenses | | 21 | | | Amortization of intangible assets | 1,308 | 1,103 | | | Restructuring charges and certain acquisition-related costs | 102 | 9 | | | | | Other (income)/deductionsnet | 680 | 275 | | | Income from continuing operations before provision/(benefit) for taxes on income | 3,421 | 6,2","filed_date":"2024-05-08","accession":"0000078003-24-000107","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000107.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":6,"context":"nd defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our res","filed_date":"2024-05-08","accession":"0000078003-24-000107","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000107.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"or a Directors spouse, serves as an executive officer, which amount to less than 2% of that organizations latest publicly available total revenues (or $1 million, whichever is greater).Drs. Desmond-Hellmann, Hobbs, Hockfield and Littman, and Mr. Echevarria, are employed at medical, scientific or academic institutions with which Pfizer engages in ordinary-course business transactions. Mr. Narayen is t","filed_date":"2024-03-14","accession":"0000078003-24-000068","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"rs, as well as the maximum potentialpayouts. Based on the results of these assessments, the Committee does not believe that the compensation programs create risks that are reasonably likely to have a material adverse effect on our company. Leading Compensation Practices | | | What We Do | What We Do Not Do | | | | Risk Mitigation | | Permit Hedging or Pledging of Pfizer Stock | | | | Compensation Recovery/Clawback | | P","filed_date":"2024-03-14","accession":"0000078003-24-000068","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":40,"context":"(Principles) contain detailed procedures to be followed in the event that one or more Directors do not receive a majority of the votes cast for his or her election at the Annual Meeting. Each nominee elected as a Director will continue in office until our next Annual Meeting and until his or her successor has been duly elected and qualified, or until a Directors earlier death, resignation, removal or retirement. While","filed_date":"2024-03-14","accession":"0000078003-24-000068","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":44,"context":"de the U.S. and is led by the Chief International Commercial Officer, Executive Vice President. In the fourth quarter of 2022, we began taking steps through our Transforming to a More Focused Company restructuring program to optimize our end-to-end R&D operations to reduce costs and cycle times as well as to further prioritize our internal R&D portfolio in areas where our capabilities are differentiated while increasi","filed_date":"2024-02-22","accession":"0000078003-24-000039","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":17,"context":"World | | | Developed Rest of World | Includes the following markets: Japan, Canada, South Korea, Australia and New Zealand | | | EC | European Commission | | | EMA | European Medicines Agency | | | Emerging Markets | Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Central Europe, the Middle East, Africa and Turkey | | | EPS | earnin","filed_date":"2024-02-22","accession":"0000078003-24-000039","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"d monetary policy actions in countries experiencing high inflation or deflation rates; any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues; the impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain; any significant issues related to the outsourcing of certain operationa","filed_date":"2024-02-22","accession":"0000078003-24-000039","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":24,"context":"| Collaboration and Co-Promotion Agreements | 5 | | | International Operations | 6 | | | Sales and Marketing | 6 | | | Patents and Other Intellectual Property Rights | 7 | | | Competition | 10 | | | Pricing Pressures and Managed Care Organizations | 10 | | | Raw Materials | 11 | | | Government Regulation and Price Constraints | 11 | | | Environmental Matters | 14 | | | Our People | 15 | | | ITEM1A. RISK FACTORS","filed_date":"2024-02-22","accession":"0000078003-24-000039","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":62,"context":"995. The occurrence of any of the risks identified below, in the [Item 1A. Risk Factors](#i2a2412fd329d412096454ccea3d9368c_67) section, or within MD&A, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results of operations, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequent","filed_date":"2024-02-22","accession":"0000078003-24-000039","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"ght to commercialization globally, outside of the U.S. Upon the closing of the transaction on January4, 2022, we paid Biohaven $500 million, including an upfront payment of $150 million and an equity investment of $350 million. We recognized $263 million for the upfront payment and premium paid on our equity investment in Acquired in-process research and development expenses. In October 2022, we acquired all outstanding co","filed_date":"2024-02-22","accession":"0000078003-24-000039","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":12,"context":"ess research and development expenses(5) | | 73 | | | 73 | | | | | 194 | | | 953 | | | (80) | | | Amortization of intangible assets | | 1,267 | | | 1,130 | | | 12 | | 4,733 | | | 3,609 | | | 31 | | | Restructuring charges and certain acquisition-related costs(6) | | 2,566 | | | 795 | | | * | | 2,943 | | | 1,375 | | | * | | | | | | | | | | | | | | | | | | Other (income)deductionsnet(7) | | (480) | | | (846) | | | (43)","filed_date":"2024-01-30","accession":"0000078003-24-000017","full_text":"https://origin.rootz.global/static/filing/0000078003-24-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":20,"context":"7,813 | | | | Acquired in-process research and development expenses | | 67 | | | 524 | | | 122 | | | 880 | | | | Amortization of intangible assets | | 1,179 | | | 822 | | | 3,466 | | | 2,478 | | | | Restructuring charges and certain acquisition-related costs | | 155 | | | 199 | | | 377 | | | 580 | | | | | | | | | | | | | | | Other (income)/deductionsnet | | (79) | | | (59) | | | (356) | | | 1,063 | | | | Income/(loss","filed_date":"2023-11-08","accession":"0000078003-23-000115","full_text":"https://origin.rootz.global/static/filing/0000078003-23-000115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":7,"context":"nd defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our res","filed_date":"2023-11-08","accession":"0000078003-23-000115","full_text":"https://origin.rootz.global/static/filing/0000078003-23-000115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"5443f79e_40), including the proposed acquisition of Seagen, as well as the following: Proposed Acquisition of Telavant Holdings, Inc. (Telavant)In October 2023, we and Roivant Sciences Ltd. (Roivant) entered into a definitive agreement with Roche Holdings Inc. (Roche) through which Roche would acquire Telavant for an upfront payment of $7.1 billion and a contingent milestone payment of $150 million. Roivant currently owns approxima","filed_date":"2023-11-08","accession":"0000078003-23-000115","full_text":"https://origin.rootz.global/static/filing/0000078003-23-000115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":12,"context":"research and development expenses(4) | | 67 | | | 524 | | | (87) | | 122 | | | 880 | | | (86) | | | Amortization of intangible assets | | 1,179 | | | 822 | | | 43 | | 3,466 | | | 2,478 | | | 40 | | | Restructuring charges and certain acquisition-related costs(5) | | 155 | | | 199 | | | (22) | | 377 | | | 580 | | | (35) | | | | | | | | | | | | | | | | | | Other (income)deductionsnet(6) | | (79) | | | (59) | | | 33 | |","filed_date":"2023-10-31","accession":"0000078003-23-000111","full_text":"https://origin.rootz.global/static/filing/0000078003-23-000111.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":18,"context":"| | 5,116 | | | | Acquired in-process research and development expenses | | 33 | | | 1 | | | 55 | | | 356 | | | | Amortization of intangible assets | | 1,184 | | | 822 | | | 2,287 | | | 1,657 | | | | Restructuring charges and certain acquisition-related costs | | 214 | | | 189 | | | 222 | | | 381 | | | | | | | | | | | | | | | Other (income)/deductionsnet | | (347) | | | 772 | | | (277) | | | 1,122 | | | | Income from","filed_date":"2023-08-09","accession":"0000078003-23-000088","full_text":"https://origin.rootz.global/static/filing/0000078003-23-000088.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":13,"context":"ealand | | | Developed Rest of World | Includes the following markets: Japan, Australia, Canada, South Korea and New Zealand | | | EC | European Commission | | | EMA | European Medicines Agency | | | Emerging Markets | Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Central Europe, the Middle East, Africa and Turkey | | | EPS | earnin","filed_date":"2023-08-09","accession":"0000078003-23-000088","full_text":"https://origin.rootz.global/static/filing/0000078003-23-000088.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":7,"context":"nd defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our res","filed_date":"2023-08-09","accession":"0000078003-23-000088","full_text":"https://origin.rootz.global/static/filing/0000078003-23-000088.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PFE","company":"PFIZER INC","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":12,"context":"ocess research and development expenses(3) | | 33 | | | 1 | | | * | | 55 | | | 356 | | | (85) | | | Amortization of intangible assets | | 1,184 | | | 822 | | | 44 | | 2,287 | | | 1,657 | | | 38 | | | Restructuring charges and certain acquisition-related costs(4) | | 214 | | | 189 | | | 13 | | 222 | | | 381 | | | (42) | | | | | | | | | | | | | | | | | | Other (income)deductionsnet(5) | | (347) | | | 772 | | | * | | (27","filed_date":"2023-08-01","accession":"0000078003-23-000085","full_text":"https://origin.rootz.global/static/filing/0000078003-23-000085.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"90917bfd9afdb90fe65768a06c1f230a89c1f83554a97e2ae1ba5cd3e59cfc36","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"f5db7cc75e3f937a25e608dc67d2fb77f55374b42c1f208557dff9be0b0763d7","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":22,"hourly_limit":500,"remaining":478,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}